2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4474 Safety and efficacy of chimeric antigen receptor T-cell therapy in octogenarians with hematologic malignancies

Hannah Zhong, Tamer Othman, MD2, Yan Wang3, Stacy Pak, PharmD4, Geoffrey Shouse, DO PhD5, John Baird, MD6, James Godfrey, MD7, Scott R Goldsmith, MD8, Matthew Mei I, MD9, Tycel Phillips, MD, FASCO10, Swetha Thiruvengadam, MD11, Ibrahim Aldoss, MD12, Alex Francisco Herrera, MD13, Michael Rosenzweig, MD14, Stephen J. Forman, MD15, Tanya Siddiqi, MD16, Ahmed Aribi, MD17, Myo Htut, MD18, L. Elizabeth Elizabeth Budde, MD PhD19
1 City of Hope National Medical Center, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 City of Hope National Medical Center, Duarte, California, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 City of Hope National Medical Center, Duarte, California, United States
14 City of Hope National Medical Center, Duarte, California, United States
15 City of Hope National Medical Center, Duarte, California, United States
16 City of Hope National Medical Center, Duarte, California, United States
17 City of Hope National Medical Center, Duarte, California, United States
18 City of Hope National Medical Center, Duarte, California, United States
19 City of Hope National Medical Center, Duarte, California, United States

Background: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory hematologic malignancies; however, patients aged ≥80 years remain underrepresented in clinical trials, and data to guide patient selection in this group remain limited. We report a single-center experience evaluating the safety and efficacy of CAR T-cell therapy in octogenarians across hematologic malignancies. 

Methods: We conducted a single-center retrospective study of patients ≥80 years old with hematologic malignancies who received a commercial CAR T product between 07/23/2019 and 05/04/2026. (COH Institutional Review Board #260417) The primary endpoint was safety, as measured by incidence of Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity (ICANS), infections, Immune Effector Cell-Associated Hematotoxicity (ICAHT), and Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS). Secondary endpoints were response rate, progression-free survival (PFS), overall survival (OS), healthcare resource utilization, and discharge disposition. CRS and ICANS were graded by ASTCT criteria and ICAHT by EHA/EBMT consensus criteria; survival was estimated by the Kaplan-Meier method. 

Results: Thirty-one patients were included. The median age was 81 years (range, 80-86) and 71% (22) were male. Race was White (77%), Asian (19%), Black (3%), and Hispanic (26%). Baseline ECOG performance status was 0 in 45% of patients, 1 in 45%, and ≥2 in 10%. Diagnoses were large B-cell lymphoma (LBCL) in 71% (n=22), multiple myeloma (MM) in 19% (n=6), one patient each with acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Patients received a median of 2 prior lines of therapy (range, 1-9). Bulky disease at lymphodepletion was present in 13% (3/24) of lymphoma patients and 33% (2/6) of MM patients had a high disease burden; the patient with ALL had detectable measurable residual disease by next generation sequencing. Bridging therapy was required in 77% (24) of patients. Prophylactic dexamethasone 10mg daily was given to 7 patients (3 doses in 6 and 2 doses in 1).  

The incidence of any grade (and grade ≥3) CRS, ICANS, and ICAHT were 71% (0%), 29% (16%), 3% (0%), respectively, and no patient developed IEC-HS. The median onset and duration were 2 days (range, 0-5) and 3 days (range, 1-5) for CRS, and 7 days (range, 0-11) and 5 days (range, 1-47) for ICANS. Tocilizumab was given to 48% (15) with a median 1 dose (range, 1-4); 45% (14) received a median prednisone equivalent dose of 57mg (range, 10-3308). Infection with the first 100 days occurred in 19% (6) of patients, including one grade 3 event. There were no treated related deaths.  

Excluding 2 lymphoma patients who were in complete remission (CR) at time of lymphodepletion and remained in CR post CAR T, the overall response rate in lymphoma, MM, and ALL were 82% (18/22), 83% (5/6), and 100% (1/1), respectively. In LBCL, the median PFS was 17 months (95%CI: 3-49) with 1-year PFS of 52% (95%CI: 29-71%); median OS was 32 months (95%CI: 12-50) with 1 year OS of 70% (95%CI: 45-86%) after a median follow-up of 20 months (range, 2.5-56.6) among the surviving patients. In MM, the median PFS was 14.5 months (95%CI: 1-not reached [NR]) with 1-year PFS of 63% (95%CI: 14-89%); the median OS was NR with 1-year OS of 60% (95%CI: 13-88%) after a median follow-up of 20 months (range, 2.3-27.4) among the surviving patients. 

CAR T was administered in the outpatient setting in 58% (18), of whom 89% (16) were subsequently admitted for toxicity management with a median length of stay of 3 days (range, 1-15). One patient required intensive care in the first 100 days. The median number of packed red blood cell, platelet transfusion, granulocyte colony stimulating factor doses, and intravenous immunoglobulin infusions during the first year were 0 (range, 0-12), 0 (range, 0-19), 2 (range, 0-12), and 0 (range, 0-4), respectively. Two patients required thrombopoietin receptor agonist for insufficient platelet recovery. After initial hospitalization, 13% (4) of patients were discharged to a skilled nursing facility. 

Conclusions: In carefully selected patients aged ≥80 years, commercial CAR T-cell therapy demonstrated manageable toxicity, and encouraging clinical outcomes. These findings support that chronological age alone should not preclude consideration of CAR T-cell therapy in otherwise medically fit patients.  

Hannah Zhong: No relevant conflicts of interest to declare.